Expression pattern of the CXCL12/CXCR4–CXCR7 trio in Kaposi sarcoma skin lesions. (1st December 2016) - Desnoyer, A.
Summary: Background: Recent studies have independently implicated the chemokine CXCL12 and its receptors, CXCR4 and CXCR7, in the pathophysiology of Kaposi sarcoma (KS). Objectives: We investigated whether the CXCL12/CXCR4–CXCR7 protein trio could constitute KS biomarkers. Methods: Endothelial and spindle cells positive for CXCL12/CXCR4–CXCR7, human herpesvirus‐8 latency‐associated nuclear antigen (LANA), Ki67 antigen (proliferation) and vascular endothelial growth factor (VEGF) were quantitated in skin lesions from patients with AIDS‐associated KS, patients with classic KS and patients with angiomas, using immunohistochemistry and quantitative image analysis (16, 21 and 20 skin lesions, respectively). Plasma CXCL12 concentrations were measured by enzyme‐linked immunosorbent assay from 20 patients with AIDS‐KS, 12 HIV‐infected patients without KS and 13 healthy donors' samples. Results: Cells positive for CXCL12, CXCR4, CXCR7, LANA, Ki67 and VEGF were significantly enriched in patients with AIDS‐associated KS and classic KS vs. angiomas ( P < 0·001), and in nodular vs. macular/papular KS lesions ( P < 0·05). CXCL12, CXCR4 and CXCR7 detection correlated with LANA, Ki67 and VEGF detection ( r > 0·4; P < 0·05). However, plasma CXCL12 concentrations did not differ between patients with AIDS‐associated KS, HIV‐infected patients without KS, and healthy donors. Conclusions: The CXCL12/CXCR4–CXCR7 trio is upregulated in KS and correlates with KS pathophysiological markers and the severity of skin lesions. Histological assessment of the CXCL12 axis could serve as a valuable biomarker for KS diagnosis and progression.